FY2026 EPS Estimates for Amgen Increased by Erste Group Bank

Key Points

• Erste Group Bank raised Amgen’s FY2026 EPS forecast to $23.05 from $22.41, slightly above the $22.97 consensus estimate. The bank maintained a “Hold” rating.
• Amgen’s latest quarter exceeded expectations, reporting EPS of $6.29 versus $5.62 expected and revenue of $10.05 billion versus $9.43 billion, while revenue grew 9.5% year over year. The company’s FY2026 EPS guidance remains $22.30–$23.50.
• Analysts broadly maintain a “Hold” consensus, with a target price of $380.43, while Amgen’s shares recently traded at $432.42. The company also announced a quarterly dividend of $2.52 per share, representing a 2.3% annualized yield.

Amgen Inc. (NASDAQ:AMGN - Free Report) - Investment analysts at Erste Group Bank raised their FY2026 EPS estimates for Amgen in a report issued on Thursday, August 27th. Erste Group Bank analyst H. Engel now forecasts that the medical research company will post earnings per share of $23.05 for the year, up from their prior estimate of $22.41. Erste Group Bank currently has a "Hold" rating on the stock. The consensus estimate for Amgen's current full-year earnings is $22.97 per share.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating the consensus estimate of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The firm had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. During the same quarter in the previous year, the firm posted $6.02 earnings per share. The company's revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS.

A number of other research firms also recently issued reports on AMGN. Barclays increased their price target on Amgen from $360.00 to $380.00 and gave the stock an "equal weight" rating in a research report on Friday, August 14th. Cantor Fitzgerald lifted their price objective on Amgen from $350.00 to $400.00 and gave the company a "neutral" rating in a report on Tuesday, August 18th. Daiwa Securities Group lowered their price objective on shares of Amgen from $410.00 to $390.00 and set an "outperform" rating for the company in a research note on Wednesday, May 13th. Bank of America increased their target price on shares of Amgen from $312.00 to $317.00 and gave the stock an "underperform" rating in a report on Wednesday, August 5th. Finally, Citigroup raised their target price on shares of Amgen from $345.00 to $405.00 and gave the company a "neutral" rating in a research report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have issued a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $380.43.

Amgen Stock Performance

AMGN opened at $432.42 on Monday. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. The stock's fifty day moving average is $388.64 and its two-hundred day moving average is $364.63. The company has a market capitalization of $233.78 billion, a P/E ratio of 26.88, a PEG ratio of 3.12 and a beta of 0.41. Amgen has a 52 week low of $269.77 and a 52 week high of $447.03.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be paid a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date is Friday, August 21st. Amgen's dividend payout ratio is 62.65%.

Insider Transactions at Amgen

In related news, SVP Rachna Khosla sold 1,252 shares of the firm's stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $416.43, for a total transaction of $521,370.36. Following the sale, the senior vice president owned 6,404 shares of the company's stock, valued at $2,666,817.72. This trade represents a 16.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Nancy A. Grygiel sold 2,970 shares of Amgen stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the transaction, the senior vice president owned 7,340 shares in the company, valued at $2,951,854.40. This trade represents a 28.81% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 6,222 shares of company stock worth $2,540,926. 0.85% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of AMGN. Rational Advisors Inc. boosted its position in shares of Amgen by 13.7% during the 2nd quarter. Rational Advisors Inc. now owns 199 shares of the medical research company's stock worth $72,000 after purchasing an additional 24 shares in the last quarter. Beacon Financial Advisory LLC increased its holdings in shares of Amgen by 2.0% in the 2nd quarter. Beacon Financial Advisory LLC now owns 1,274 shares of the medical research company's stock valued at $461,000 after purchasing an additional 25 shares in the last quarter. Legacy Financial Advisors Inc. increased its holdings in shares of Amgen by 0.8% in the 2nd quarter. Legacy Financial Advisors Inc. now owns 3,407 shares of the medical research company's stock valued at $1,234,000 after purchasing an additional 26 shares in the last quarter. Roman Butler Fullerton & Co. lifted its stake in shares of Amgen by 1.4% in the second quarter. Roman Butler Fullerton & Co. now owns 1,956 shares of the medical research company's stock valued at $705,000 after purchasing an additional 27 shares during the period. Finally, High Note Wealth LLC lifted its stake in shares of Amgen by 5.8% in the fourth quarter. High Note Wealth LLC now owns 508 shares of the medical research company's stock valued at $166,000 after purchasing an additional 28 shares during the period. Institutional investors own 76.50% of the company's stock.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Tezspire expands its potential market. Amgen and AstraZeneca reported that Tezspire met both co-primary and all key secondary endpoints in the Phase 3 CROSSING study for eosinophilic esophagitis (EoE). Improvements in tissue inflammation and swallowing symptoms were statistically significant, clinically meaningful and sustained through 52 weeks. EoE could become Tezspire’s third approved indication, adding a potentially significant growth opportunity beyond asthma and chronic rhinosinusitis with nasal polyps. Tezspire Phase 3 EoE Results
• Positive Sentiment: Recent financial performance remains supportive. Amgen’s latest reported quarter exceeded analyst expectations for both earnings and revenue, with revenue increasing year over year. Strong results and full-year guidance have helped keep the stock near its 52-week high and provide a favorable backdrop for pipeline news. Amgen Earnings and Guidance
• Neutral Sentiment: Additional pipeline updates offer limited near-term valuation impact. Amgen provided updates on a pediatric psoriasis study involving apremilast and began a Phase 1 trial of AMG 691 aimed at markets in Asia. These programs may support long-term growth, but both remain too early to materially affect current earnings expectations. Amgen Pediatric Psoriasis Study
• Negative Sentiment: Amgen ended its Crohn’s disease research partnership with TScan Therapeutics. Terminating the collaboration removes an external source of potential inflammatory bowel disease assets and may raise questions about the company’s strategy in this research area. The impact is likely limited near term because the program was still focused on target discovery. Amgen Ends Crohn’s Research Partnership

About Amgen

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source